Toxicology

Philip Morris International to Host Webcast of 2023 Fourth-Quarter and Full-Year Results

Retrieved on: 
Thursday, February 1, 2024
Tobacco, Retail, Smoke, Philip Morris International, Life, Research, PMI, IQOS, Q&A, Food, Swedish Match, Sale, Webcast, Toxicology, ZYN

Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at www.pmi.com/2023Q4earnings on Thursday, February 8, 2024, at 9:00 a.m.

Key Points: 
  • Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at www.pmi.com/2023Q4earnings on Thursday, February 8, 2024, at 9:00 a.m.
  • ET, to discuss its 2023 Fourth-Quarter and Full-Year financial results, which will be issued at approximately 7:00 a.m.
  • An archived recording of the webcast, in addition to the slides and script, will be available at www.pmi.com/2023Q4earnings .
  • Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Retrieved on: 
Thursday, February 1, 2024
Health Technology, Technology, Cannabis, Pharmaceutical, Seniors, Artificial Intelligence, Natural Resources, Clinical Trials, Other Technology, Vitamins, Supplements, Biotechnology, Science, Other Science, Consumer, Research, Health, APP, Anxiety, Agitation, Peptide, Plaque, Machine learning, IGC, Artificial intelligence, Mouse, Dementia, Amyloid, Toxicology, Movement

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease.
  • Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models.
  • In line with IGC Pharma's artificial intelligence and machine learning ("AI/ML") initiatives, we plan to leverage cutting-edge AI/ML tools for studying TGR-63's toxicology and protein interactions.
  • The results from these multiple tests indicate that TGR-63 treatment helped normalize emotional and behavioral responses in our Alzheimer's mouse model, reinforcing its potential as a promising treatment.

Government of Canada announces appointments to the Canadian Institutes of Health Research Governing Council

Retrieved on: 
Wednesday, January 31, 2024
Knowledge, Partnership, Medicine, Mental health, University of Toronto, CIHR, Hospital, Institute of Medical Sciences, First Nations, Research, University, Evaluation, Sustainability, Social work, Personal ordinariate, Pharmacology, Faculty, Public health, Management, Addiction, Public, Mental, St. Michael's Hospital, Toxicology, Democracy, CAMH, Parliament, Organization

Dr. Bernard Le Foll is a senior scientist specializing in drug addiction within the Institute for Mental Health Policy Research at the Centre for Addiction and Mental Health (CAMH).

Key Points: 
  • Dr. Bernard Le Foll is a senior scientist specializing in drug addiction within the Institute for Mental Health Policy Research at the Centre for Addiction and Mental Health (CAMH).
  • He is also Vice-President Research and Academics and Chief Scientific Officer of the Waypoint Centre for Mental Health Care.
  • "I am very pleased to announce three appointments to the Canadian Institutes of Health Research (CIHR) Governing Council.
  • The Canadian Institutes of Health Research (CIHR) is part of the Health Portfolio, which supports the Minister of Health in maintaining and improving the health of Canadians.

Global Consulting Firm J.S. Held Releases Expert Insights on Carbon Management: Issues in Greenhouse Gas Management

Retrieved on: 
Wednesday, January 31, 2024
Carbon, Biophysical environment, ESG, Pressure, European, Consultant, Data management, Non-governmental organization, Environment, Climate change, GHG, Epidemiology, Environment, health and safety, Risk, Environmental Health (journal), Climate, Toxicology, EHS, Organization, Renewable energy

JERICHO, N.Y., Jan. 31, 2024 /PRNewswire-PRWeb/ -- Global consulting firm J.S. Held announces the publication of an insightful article on Carbon Management written by one of the sustainability experts in J.S. Held's Environmental, Health, and Safety (EHS) practice. The article delves deeply into the complexities of Carbon Management, discussing its likely impacts on organizations and providing a high-level strategic checklist for responding to new carbon management requirements effectively, which is of value to all industries and companies facing demand for greater transparency of environmental performance.

Key Points: 
  • Held's sustainability expert unveils crucial insights on the forthcoming 2024 carbon reporting regulations and developing carbon strategies regarding climate change and greenhouse gas issues.
  • Held announces the publication of an insightful article on Carbon Management written by one of the sustainability experts in J.S.
  • The article "Carbon Management: Issues in Greenhouse Gas Management" discusses the growing complexity surrounding carbon management and greenhouse gas (GHG) reduction for companies across various industries.
  • To gain deeper insights into the impact of Carbon Management regulations and to explore more ways to develop carbon strategies, please read the full article here: https://www.jsheld.com/insights/articles/carbon-management-issues-in-gre... .

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Monday, January 22, 2024
Brain, Type 2, LMD, Legislation, Incidence, C-peptide, Cancer, SNY, Panobinostat, GBM, Letter, Trial of the century, Neoplasm, CFO, Diffusion, Cell proliferation, Central nervous system, Apoptosis, Type 1 diabetes, Patent, Breast, Metabolism, Diffuse intrinsic pontine glioma, Type 2 diabetes, Survival, DIPG, MGMT, Patient, Toxicology, Glioblastoma, Tolimidone, Pfizer, Insulin, OXPHOS, Plasma, Oxidative phosphorylation, FDA, Progression-free survival, Convection, Columbia University, Type 1, Cerebrospinal fluid, DMG, Pharmaceutical industry

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Verastem Oncology, Patient, Accelerated approval (FDA), Toxicology, GLP, BIW, Part, Diagnosis, Safety, RAMP, Cancer, NSCLC, IND, Food, NDA, RAS, Lung cancer, FDA, Avutometinib, QD, Pancreatic cancer, Pharmaceutical industry

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.
  • “We have made significant progress in our commitment to advancing new solutions for RAS pathway-driven cancers and look forward to an exciting and catalyst-filled year ahead.
  • Safety and tolerability continued to be favorable and consistent with previously reported data.
  • Entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.

In Vitro Toxicology Testing Market Research Report 2023 - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 23, 2024
Science, Other Science, Research, Pharmaceutical, Health, Cosmetics, Retail, Other Health, European, Toxicology, Food, Animal, ELISA, Equipment, ADME, Drug discovery, Investment, USD, Patent, Consumables, Growth, Medical device

The "In Vitro Toxicology Testing Market by Product & Service (Assays (ELISA & Western Blot), Equipment, Consumable, Software), Toxicity Endpoints (ADME, Genotoxicity, Cytotoxicity), Technology, Method, Industry (Pharma, Cosmetics) - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Toxicology Testing Market by Product & Service (Assays (ELISA & Western Blot), Equipment, Consumable, Software), Toxicity Endpoints (ADME, Genotoxicity, Cytotoxicity), Technology, Method, Industry (Pharma, Cosmetics) - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • In 2022, the consumables segment accounted for the largest share of products & services in the global In vitro toxicology testing market.
  • Furthermore, the market share of the consumables market is expected to grow simultaneously with the increasing adoption of in vitro toxicology testing across various industries.
  • Europe has continued to dominate the in vitro toxicology testing market during the forecast period of 2023-2028.

SMOK APPEALS FDA MARKETING DENIAL ORDER TO U.S. COURT OF APPEALS FOR THE FIFTH CIRCUIT

Retrieved on: 
Saturday, January 20, 2024
Student, Toxicology, Multimedia, Laboratory, FDA, Marketing, Pharmaceutical industry

The appeal, which was joined by a Dallas, Texas-based distributor of the subject SMOK products, was filed with the New Orleans, Louisiana-based U.S. Court of Appeals for the Fifth Circuit.

Key Points: 
  • The appeal, which was joined by a Dallas, Texas-based distributor of the subject SMOK products, was filed with the New Orleans, Louisiana-based U.S. Court of Appeals for the Fifth Circuit.
  • On January 16, 2024, FDA announced via a press release that it had issued a marketing denial order on the premarket tobacco product applications for the subject open-system SMOK products because the applications supposedly "failed to provide sufficient data to characterize constituent delivery, product stability, and product abuse liability."
  • Shenzhen IVPS also noted that FDA's press release announcing the marketing denial order was misleading in its characterization of the supposed levels of youth use of SMOK products, as FDA claimed that the 2023 National Youth Tobacco Survey showed "11.3% of middle and high school students reporting past 30-day use of SMOK products."
  • The United States Court of Appeals for the Fifth Circuit recently vacated two other marketing denial orders FDA issued to bottled e-liquid manufacturers in 2021, finding that FDA engaged in springing new study requirements on manufacturers months after they were required to file their applications without adequate notice or opportunity for the applicants to satisfy the new study requirements.

3D Cell Culture Market Size and Share to Surpass USD 8.9 Billion by 2035 | Roots Analysis

Retrieved on: 
Tuesday, January 16, 2024
Biotron, Regenerative medicine, Research, Toxicology, Incidence, B cell, Extracellular matrix, Immortalised cell line, ECM, Tissue, Drug discovery, Zeiss, Tissue engineering, 3D, Drug development, FDA, Microcarrier, Growth, 3D printing

LONDON, Jan. 16, 2024 /PRNewswire/ -- 

Key Points: 
  • Also, the maintenance of 3D cell culture equipment is complex and requires specialized training or skilled personnel, which enhances the overall cost of installing 3D cell culture.
  • Despite the market restraints, the 3D cell culture market is growing exponentially due to the increasing trend of personalized medicine and ongoing technological advancements to enhance the reproducibility of 3D cell culture-based experiments.
  • Based on the scaffold format, the 3D cell culture market is dominated by scaffold-based format, capturing 46% of the market share by 2035.
  • Based on the key geographical region, North America will dominate the 3D cell culture market, capturing 39% of the overall market share by 2035.

Going Beyond Plastic: Chung-Ang University Team Explores Tara Gum as a Green Polymer

Retrieved on: 
Tuesday, January 16, 2024
Seed, Nanoparticle, Research, Toxicology, Food, Polysaccharide, D-3, Behavior, Administration, Plastic, Chung-Ang University, Edible, Zinc, Safety, Chitosan, Food industry, Copper, Carbohydrate Polymers, South Korea, Pollution, Gum arabic

SEOUL, South Korea, Jan. 16, 2024 /PRNewswire/ -- Synthetic, non-biodegradable plastics are major sources of environmental pollution and have prompted a rising interest in sustainable, biodegradable alternatives derived from natural polymers. "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution. This natural, water-soluble substance contains polysaccharides (complex carbohydrates), including the widely used "galactomannan," which is employed in coatings, edible films, and as a stabilizer and thickener. The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery. Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.

Key Points: 
  • "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution.
  • The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery.
  • Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.
  • "The physicochemical property of tara gum and its products can be enhanced using various kinds of monomers, crosslinkers, or other polysaccharides.